These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37606287)

  • 1. Characterization of adnexal lesions using photoacoustic imaging to improve sonographic O-RADS risk assessment.
    Zhu Q; Luo H; Middleton WD; Itani M; Hagemann IS; Hagemann AR; Hoegger MJ; Thaker PH; Kuroki LM; McCourt CK; Mutch DG; Powell MA; Siegel CL
    Ultrasound Obstet Gynecol; 2023 Dec; 62(6):891-903. PubMed ID: 37606287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O-RADS in differentiating between benign and malignant adnexal lesions in North American women.
    Hiett AK; Sonek JD; Guy M; Reid TJ
    Ultrasound Obstet Gynecol; 2022 May; 59(5):668-676. PubMed ID: 34533862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses.
    Xie WT; Wang YQ; Xiang ZS; Du ZS; Huang SX; Chen YJ; Tang LN
    J Ovarian Res; 2022 Jan; 15(1):15. PubMed ID: 35067220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External Validation of O-RADS US Risk Stratification and Management System.
    Hack K; Gandhi N; Bouchard-Fortier G; Chawla TP; Ferguson SE; Li S; Kahn D; Tyrrell PN; Glanc P
    Radiology; 2022 Jul; 304(1):114-120. PubMed ID: 35438559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Performance of Ultrasonography-Based Risk Models in Differentiating Between Benign and Malignant Ovarian Tumors in a US Cohort.
    Yoeli-Bik R; Longman RE; Wroblewski K; Weigert M; Abramowicz JS; Lengyel E
    JAMA Netw Open; 2023 Jul; 6(7):e2323289. PubMed ID: 37440228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of American College of Radiology Ovarian-Adnexal Reporting and Data System ultrasound to predict malignancy risk in adnexal lesions.
    Li Y; Shao G; Wu M; Zhang F; Zhang Y; Shao C
    J Obstet Gynaecol Res; 2024 Feb; 50(2):225-232. PubMed ID: 37990446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Combing O-RADS US and CA-125 Improve Diagnostic Accuracy in Assessing Adnexal Malignancy Risk in Women With Different Menopausal Status?
    Wu M; Wang Q; Zhang M; Cao J; Chen Y; Zheng J; Luo L; Su M; Lin X; Kuang X; Zhang X
    J Ultrasound Med; 2023 Feb; 42(3):675-685. PubMed ID: 35880406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic performance of IOTA SR and O-RADS combined with CA125, HE4, and risk of malignancy algorithm to distinguish benign and malignant adnexal masses.
    Yang Y; Ju H; Huang Y
    Eur J Radiol; 2023 Aug; 165():110926. PubMed ID: 37418798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the O-RADS and ADNEX models regarding malignancy rate and validity in evaluating adnexal lesions.
    Chen GY; Hsu TF; Chan IS; Liu CH; Chao WT; Shih YC; Jiang LY; Chang YH; Wang PH; Chen YJ
    Eur Radiol; 2022 Nov; 32(11):7854-7864. PubMed ID: 35583711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving risk stratification of indeterminate adnexal masses on MRI: What imaging features help predict malignancy in O-RADS MRI 4 lesions?
    Wong BZY; Causa Andrieu PI; Sonoda Y; Chi DS; Aviki EM; Vargas HA; Woo S
    Eur J Radiol; 2023 Nov; 168():111122. PubMed ID: 37806193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses.
    Zheng H; Tie Y; Wang X; Yang Y; Wei X; Zhao X
    Medicine (Baltimore); 2019 Feb; 98(7):e14577. PubMed ID: 30762809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating Contrast-enhanced US to O-RADS US for Classification of Adnexal Lesions with Solid Components: Time-intensity Curve Analysis versus Visual Assessment.
    Wu M; Wang Y; Su M; Wang R; Sun X; Zhang R; Mu L; Xiao L; Wen H; Liu T; Meng X; Huang L; Zhang X
    Radiol Imaging Cancer; 2024 Nov; 6(6):e240024. PubMed ID: 39392388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modified CEUS risk stratification model for adnexal masses with solid components: prospective multicenter study and risk adjustment.
    Wu M; Zhang M; Qu E; Sun X; Zhang R; Mu L; Xiao L; Wen H; Wang R; Liu T; Meng X; Wu S; Chen Y; Su M; Wang Y; Gu J; Zhang X
    Eur Radiol; 2024 Sep; 34(9):5978-5988. PubMed ID: 38374482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Ovarian-Adnexal Reporting and Data System (O-RADS) US Score Effect on Surgical Resection Rate.
    Shen L; Sadowski EA; Gupta A; Maturen KE; Patel-Lippmann KK; Zafar HM; Kamaya A; Antil N; Guo Y; Barroilhet LM; Jha P
    Radiology; 2024 Oct; 313(1):e240044. PubMed ID: 39377674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External Validation of the Ovarian-Adnexal Reporting and Data System (O-RADS) Lexicon and the International Ovarian Tumor Analysis 2-Step Strategy to Stratify Ovarian Tumors Into O-RADS Risk Groups.
    Timmerman S; Valentin L; Ceusters J; Testa AC; Landolfo C; Sladkevicius P; Van Holsbeke C; Domali E; Fruscio R; Epstein E; Franchi D; Kudla MJ; Chiappa V; Alcazar JL; Leone FPG; Buonomo F; Coccia ME; Guerriero S; Deo N; Jokubkiene L; Kaijser J; Scambia G; Andreotti R; Timmerman D; Bourne T; Van Calster B; Froyman W
    JAMA Oncol; 2023 Feb; 9(2):225-233. PubMed ID: 36520422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review and Meta-Analysis of O-RADS Ultrasound and O-RADS MRI for Risk Assessment of Ovarian and Adnexal Lesions.
    Zhang Q; Dai X; Li W
    AJR Am J Roentgenol; 2023 Jul; 221(1):21-33. PubMed ID: 36722758
    [No Abstract]   [Full Text] [Related]  

  • 17. Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses.
    Cao L; Wei M; Liu Y; Fu J; Zhang H; Huang J; Pei X; Zhou J
    Gynecol Oncol; 2021 Jul; 162(1):107-112. PubMed ID: 33966893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of ADNEX and IOTA two-step strategy and estimation of risk of complications during follow-up of adnexal masses in low-risk population.
    Pascual MA; Vancraeynest L; Timmerman S; Ceusters J; Ledger A; Graupera B; Rodriguez I; Valero B; Landolfo C; Testa AC; Bourne T; Timmerman D; Valentin L; Van Calster B; Froyman W
    Ultrasound Obstet Gynecol; 2024 Sep; 64(3):395-404. PubMed ID: 38477179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Added Value of Quantitative Analysis of Diffusion-Weighted Imaging in Ovarian-Adnexal Reporting and Data System Magnetic Resonance Imaging.
    Hottat NA; Badr DA; Van Pachterbeke C; Vanden Houte K; Denolin V; Jani JC; Cannie MM
    J Magn Reson Imaging; 2022 Jul; 56(1):158-170. PubMed ID: 34797013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of the gynecology imaging reporting and data system (GI-RADS) with the ovarian malignancy marker CA-125 in preoperative adnexal tumor assessment.
    Migda M; Bartosz M; Migda MS; Kierszk M; Katarzyna G; Maleńczyk M
    J Ovarian Res; 2018 Nov; 11(1):92. PubMed ID: 30390688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.